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Abstract 
Background: Hearing loss and ovarian dysfunction are key features of Perrault syndrome (PRLTS) but the clinical and 
pathophysiological features of hearing impairment in PRLTS individuals have not been addressed. Mutations in one of 
five different genes HSD17B4, HARS2, LARS2, CLPP or TWNK (previous symbol C10orf2) cause the autosomal recessive 
disorder but they are found only in about half of the patients.
Methods: We report on two siblings with a clinical picture resembling a severe, neurological type of PRLTS. For an 
exhaustive characterisation of the phenotype neuroimaging with volumetric measurements and objective measures 
of cochlear hair cell and auditory nerve function (otoacustic emissions and auditory brainstem responses) were used. 
Whole exome sequencing was applied to identify the genetic cause of the disorder. Co-segregation of the detected 
mutations with the phenotype was confirmed by Sanger sequencing. In silico analysis including 3D protein structure 
modelling was used to predict the deleterious effects of the detected variants on protein function.
Results: We found two rare biallelic mutations in TWNK, encoding Twinkle, an essential mitochondrial helicase. Muta-
tion c.1196A>G (p.Asn399Ser) recurred for the first time in a patient with PRLTS and the second mutation c.1802G>A 
(p.Arg601Gln) was novel for the disorder. In both patients neuroimaging studies showed diminished cervical enlarge-
ment of the spinal cord and for the first time in PRLTS partial atrophy of the vestibulocochlear nerves and decreased 
grey and increased white matter volumes of the cerebellum. Morphological changes in the auditory nerves, their 
desynchronized activity and partial cochlear dysfunction underlay the complex mechanism of hearing impairment in 
the patients.
Conclusions: Our study unveils novel features on the phenotypic landscape of PRLTS and provides further evidence 
that the newly identified for PRLTS TWNK gene is involved in its pathogenesis.
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Background
Perrault syndrome (PRLTS) is suspected in a female with 
bilateral sensorineural hearing loss (SNHL), ovarian 
dysfunction that may occur in a mild (primary ovarian 
insufficiency) or severe (ovarian dysgenesis) form and a 
normal 46,XX karyotype [1]. In males PRLTS is mani-
fested by SNHL and their fertility is generally consid-
ered normal but this matter should be regarded with 
caution due to scarcity of males with PRLTS and data 
from the animal studies [2, 3]. SNHL is usually the ini-
tial expression of PRLTS. In some patients a spectrum 
of neurologic symptoms develops over time indicating a 
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Common neurological abnormalities are motor 
and sensory neuropathy, muscle weakness and atro-
phy, hypo- or areflexia, cerebellar ataxia, limited eye 
movements, nystagmus, dyspraxia, as well as intel-
lectual deficit, developmental delay and seizures 
[4–7]. In brain magnetic resonance imaging (MRI), 
nonspecific white matter changes suggestive for 
cerebral leucodystrophy and cerebellar atrophy are 
described [5, 6, 8]. Depending on the occurrence of 
neurologic features, a classification of PRLTS into 
type I, static and without neurologic involvement 
and type II with a progressive neurological disease 
has been proposed [7].
Transmission of PRLTS is autosomal recessive and 
over the last years five genes causative for PRLTS 
have been identified. Mutations in HSD17B4 (OMIM 
*601860; PRLTS1), encoding a peroxisomal enzyme, 
were found in four PRLTS families [9–12]. Mutations 
in HARS2 (OMIM *600783; PRLTS2) were detected 
in three families [4, 13], mutations in LARS2 (OMIM 
*604544; PRLTS4) in six families [10, 13–15], mutations 
in CLPP (OMIM *601119; PRLTS3) in seven families 
[5, 10, 13, 16, 17], and mutations in TWNK (OMIM 
*606075; PRLTS5) only in four families with PRLTS 
[6, 10, 13]. All of the four latter PRLTS genes code for 
mitochondrial proteins. Molecular etiology for PRLTS 
remains unknown in as many as 55% of the patients, 
which emphasizes a genetic heterogeneity of the syn-
drome and shows that novel disease-causing genes still 
await discovery [10, 13].
Twinkle mtDNA helicase (TWNK), located in the 
long arm of chromosome 10 (10q24.31), encodes Twin-
kle, which localizes to mitochondrial nucleoids and 
forms a hexameric or heptameric ring structures. Twin-
kle is composed of a primase and helicase domain con-
nected via a linker region, involved in stabilization of 
the oligomeric complexes of the protein. With the pri-
mase activity the protein initiates DNA replication and 
with the helicase activity unwinds DNA for replication. 
Twinkle is essential for the replication process of mito-
chondrial DNA (mtDNA) and lifetime maintenance of 
human mtDNA integrity [18, 19].
In this study, whole-exome sequencing (WES) was 
successfully applied to identify the molecular basis 
of PRLTS in the proband and her sister from a non-
consanguineous Polish family. The cardinal manifesta-
tions of PRLTS (SNHL and ovarian dysgenesis) in the 
patients were preceded and dominated by severe and 
progressive involvement of the nervous system, making 
the diagnosis not straightforward. Here, we provide a 
thorough neurological and audiological assessment of 
both patients that unveil novel features on the pheno-
typic landscape of PRLTS.
Patients and methods
Study subjects
Two affected sisters from a Polish non-consanguineous 
family and their unaffected mother were available for the 
study. The proband was born at term by Cesarean section 
after an uneventful pregnancy with 3600 g of body weight 
and an Apgar score of 1/2/3, indicating severe birth 
depression. Her psychomotor development was normal 
until the third year of age, when the motor performance 
begun to deteriorate progressively and the electromyo-
graphy (EMG) examination was abnormal (she is unable 
to run since the age of 15  years). Speech development 
was age appropriate. At 5  years of age SNHL was diag-
nosed and pathologic auditory brainstem responses 
(ABRs) were observed. She has been fitted with hear-
ing aids at the age of 13 but they were of limited benefit. 
Testing for primary amenorrhea and delayed pubertal 
development at the age of 15 revealed hypergonadotropic 
hypogonadism, streak gonads, rudimentary uterus and a 
normal female karyotype 46,XX. Hormone replacement 
therapy was introduced. At the age of 16 chronic thyroid-
itis with elevated levels of anti-thyroid peroxidase anti-
bodies was diagnosed. Nerve conduction studies at the 
age of 21 showed axonal sensorimotor polyneuropathy. 
Ophthalmological examination was unremarkable except 
for impaired eye movements (Table 1).
The proband’s sister was born at term with 2850  g of 
body weight and an Apgar score of 5/6/7. Horizontal 
nystagmus and imbalance began at the age of 11, walk-
ing was gradually deteriorating and sensorimotor poly-
neuropathy was identified. At the age of 12 SNHL and 
ovarian dysgenesis with normal female karyotype were 
diagnosed. From the age of 16 years she has a Hashimo-
to’s disease. Biochemical studies showed mildly elevated 
levels of serum lactate and creatine kinase. Metabolic 
disease screening for organic acids with gas chromatog-
raphy-mass spectrometry (GS/MS) in urine, amino acids 
and acylcarnitines with liquid chromatography-tandem 
mass spectrometry (LC–MS/MS) in dried blood spot 
and congenital disorders of glycosylation gave normal 
results. Wilson and Refsum diseases were excluded based 
on normal blood concentrations of ceruloplasmin and 
cooper and phytanic acid, respectively.
Neurological and audiological evaluation
Written informed consent was obtained from each par-
ticipant. The study was approved by the ethics committee 
at the Institute of Physiology and Pathology of Hearing 
and performed according to the Declaration of Helsinki. 
The patients underwent thorough clinical evaluation. 
Functional impairment was assessed according to spi-
nocerebellar degeneration functional score (SDFS) [20]. 
In brain and cervical spine MRI (3T Siemens Magnetom 
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Trio, 12-channel Head Matrix Coil) T1-weighted, 
T2-weighted and diffusion-weighted images were 
acquired. In addition, high-resolution 3D structural 
T1-weighted volumes were acquired using an MPRAGE 
sequence with 208 sagittal slices and an isotropic reso-
lution 0.9 ×  0.9 ×  0.9  mm. Sequence parameters were: 
TR  =  1900  ms, TE  =  2.21  ms, TI  =  900  ms, FA  =  9, 
FOV = 26 × 28.8 cm, matrix = 320 × 290, Pixel band-
width = 200 Hz/pix, iPAT = 2, TA = 5 min. Brain struc-
tures were segmented by Freesurfer version 5.3 (http://
surfer.nmr.mgh.harvard.edu/). The diameter of the vesti-
bulocochlear nerve was evaluated directly and compared 
with the neighboring facial nerve used as an internal ref-
erence. Assessment of the cochlear and vestibular com-
ponents was based on their visual comparison and with 
reference to the facial nerve. For comparisons of the cer-
ebrum and cerebellum volumes and their white and gray 
matters, age- and sex-matched controls [21–23] from the 
Internet Brain Volume Database funded by The Human 
Brain Project (http://ibvd.virtualbrain.org/) were used. A 
difference above 2.3 of the standard deviation was con-
sidered as statistically significant.
Assessment of auditory function consisted of pure-tone 
and speech audiometry, impedance audiometry, otoa-
coustic emissions (OAE) and ABRs. Hearing thresholds 
for air and bone conduction were determined at frequen-
cies 125–8000 and 250–4000 Hz, respectively, using the 
AC40 clinical audiometer (Interacoustics, Middelfart, 
Denmark) and the 10/5 dB descending-ascending thresh-
old estimation procedure [24]. Speech comprehension 
was tested using monosyllabic Polish words and the 
AC40 audiometer (Interacoustics) [25]. Acoustic imped-
ance measurements (tympanograms and stapedius reflex) 
were performed with the Zodiac 901 instrument (Madsen 
Electronics, Copenhagen, Denmark). Stapedius reflexes 
were analyzed for the frequencies 500, 1000, 2000 and 
4000 Hz in the ipsi and contralateral modes [26]. OAE 
were evoked by standard-click stimuli and 500  Hz tone 
bursts by using the ILO-292 system (Otodynamics Ltd, 
Hatfield, United Kingdom) [27–29]. ABRs were recorded 
using the Integrity V500 system (Vivosonic Inc., Toronto, 
Canada). The stimuli were 0.1  ms clicks with alternat-
ing polarity presented with 90  dB normal hearing level 
(nHL) intensity at a repetition rate of 11/s. The amplifier 
bandwidth was 30–1500 Hz and analysis time 12 ms. The 
number of sweeps required for an averaged response was 
1024 [30].
For evaluation of the vestibular endorgan function 
Fitzgerald and Hallpike bithermal caloric test with video 
eye movement recordings (Visual Eyes Micromedical 
Technologies, Chatham, USA) were used. Sinusoidal har-
monic acceleration testing at frequencies 0.01–0.32  Hz 
was conducted with a Rotational Vestibular Chair System 
2000 (Micromedical Technologies, Chatham, USA). Oto-
lith function was measured using air-conducted sound 
stimulation cervical and ocular vestibular evoked myo-
genic potentials (cVEMP, oVEMP) at 500 Hz, 95 dBnHL 
(EclipsVemp, Interacoustics, Assens, Denmark).
Table 1 Clinical features and  laboratory findings in  the 
affected family members
Clinical features Proband Sister
Sex F F
Age at disease onset, years 3 11
Age at examination, years 27 19
Disease duration 24 8
Sensorineural hearing loss +(5*) +(12*)
Ovarian dysfunction +(15*) +(12*)
 Intellectual disability – –
 Dementia – –
 Epilepsy – –
Cerebellar syndrome +(3*) +(11*)
 SDFS 3 2
 Impaired eyes movement + +
 Gaze-evoked horizontal 
nystagmus
+ +
 Gaze-evoked vertical nystag-
mus
– +
 Dysarthria + +
 Ataxia + +
 Positive Romberg’s test + +
Flaccid paresis +(?*) +(?*)
 Muscle weakness +UL < LL +UL < LL
 Muscle atrophy +UL < LL +UL < LL
 Tendon reflexes UL Diminished Diminished
 Tendon reflexes LL Absent Absent
 Gait Steppage Steppage
 High-arched palate + +
 Pes cavus and clawed toes + +




 Lactate elevation n.a. +
 CK elevation n.a. +
 FSH and LH elevation + +






 Abnormal neuroimaging + +
Numbers in brackets (*) refer to age at diagnosis, years
UL upper limbs, LL lower limbs, n.a. no data available
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Whole‑exome and Sanger sequencing
DNA was isolated from blood sample by a standard pro-
cedure. WES was performed using SureSelect Target 
Enrichment (Agilent Technologies, Palo Alto, CA, USA) 
according to the manufacturer’s protocol. The sample 
was run on 16% of a lane on HiSeq 1500 using 2 × 100 bp 
paired-end reads. All bioinformatics analysis was done 
as described previously [31]. After primarily CASAVA 
processing, all reads were aligned to the hg19 reference 
genome with the Burrows-Wheeler Alignment Tool and 
analyzed with Genome Analysis Toolkit [32]. Indel rea-
lignment, base quality score recalibration, duplicates 
elimination as well as SNP/INDEL calling were per-
formed [33]. The retrieved variants were annotated with 
ANNOVAR and converted to MS Access format for 
subsequent manual analyses. Total exon coverage by 20 
reads or more was 89% and by 10 reads or more 95.9%. 
Alignments were inspected with Integrative Genomics 
Viewer [34] and analyzed with a pipeline combining pro-
tein coding changes, splice site prediction, prevalence in 
populations, evolutionary conservation and scores from 
PolyPhen-2 [35], SIFT [36] and MutationTaster2 [37] pre-
diction algorithms of non-synonymous single-nucleotide 
variants. Sanger sequencing with 3500xL Genetic Ana-
lyzer (Applied Biosystems, Foster City, CA, USA) and 
BigDye Terminator cycle sequencing kit v. 3.1 (Applied 
Biosystems) were used to confirm the presence of vari-
ants identified by WES.
In silico protein analysis
Homologs of the human Twinkle protein were identi-
fied with a PSI-Blast [38] search (E-value threshold of 
0.005) performed against the NCBI non-redundant pro-
tein sequence database. The collected 15,000 sequences 
were initially clustered at 60% sequence identity with cd-
hit [39] and any sequences shorter than 300, longer than 
1000 amino acids or described as “hypothetical protein” 
were removed. The multiple sequence alignment of the 
twinkle family was derived using MAFFT program [40].
For preparation of the Twinkle homology model, the 
crystal structure of the gp4 protein from bacteriophage 
T7 (Protein Data Bank code1e0j) was selected as a tem-
plate after analyzing the GeneSilico Metaserver results 
[41]. The sequence-to-structure alignment between the 
Twinkle protein and the template (Additional file 1: Fig-
ure S1) was built using the consensus alignment approach 
and 3D assessment [42] based on the results of FFAS [43], 
HHSearch [44] and the alignment proposed by Fernan-
dez et al. [19]. Multiple sequence alignment of the family 
was also taken into consideration. The 3D model of the 
protein was built with MODELLER [45]. A model qual-
ity assessment was carried out using ProSA-web server 
[46]. Secondary structure elements were predicted with 
PSI-PRED [47]. Structure visualization was carried out 
with PyMOL (http://www.pymol.org).
Results
Involvement of the nervous system
The proband and her sister came to our observation at 
the age of 27 and 19, respectively. They both had progres-
sive neurologic symptoms, including postlingual pro-
gressive SNHL, cerebellar syndrome and flaccid paresis 
(Table 1) with muscle atrophy being more prominent in 
the proband.
Brain MRI in both sisters revealed considerable bilateral 
thinning of the vestibulocochlear nerve and its cochlear and 
vestibular components, which was defined as partial atro-
phy. It was more pronounced in the cochlear than in the 
vestibular nerves. Morphological signs of a subtle cerebel-
lar atrophy (widening of the sulci more pronounced in the 
vermis than in hemispheres) were found in the proband but 
not in the sister. In cervical spine MRI, a diminished cervi-
cal enlargement was observed in both patients (Fig. 1). In 
the proband volumetric measurements of the brain showed 
significantly increased cerebellum white and decreased cer-
ebellum gray matter. The results of other volumetric meas-
urements were unchanged (Table 2).
Functional alterations in vestibulocochlear pathway
In the proband and her sister, a different degree of sen-
sorineural hearing loss mainly affecting high frequencies 
has been diagnosed in pure-tone audiometry (Fig. 2a). In 
contrast to pure-tone thresholds, speech discrimination 
was unproportionally poor and the test has not been con-
tinued. In both patients, the tympanograms revealed nor-
mal middle ear function. Ipsi- and contralateral acoustic 
reflexes were absent for all tested frequencies. The anal-
ysis of OAE recordings from both patients showed the 
presence of otoacoustic emission signals in the frequency 
range up to 2 kHz in the right ear and up to 4 kHz in the 
left ear. OAE in both patients were largely consistent with 
the results of pure-tone audiometry, demonstrating a 
partially impaired function of the outer hair cells. In ABR 
recordings, no responses at the maximum level of 90 dB 
nHL were obtained biaurally in the proband (Fig.  2b) 
and her sister. Comprehensive audiological evaluation 
revealed auditory neuropathy that was accompanied by a 
certain degree of cochlear dysfunction.
In both patients bi-thermal caloric irrigation results 
were within the normal limit. Rotational testing showed 
abnormally reduced gain and increased phase at 0.01, 
0.02 and 0.04  Hz and was unaffected at the remaining 
frequencies. In the proband cVEMP and oVEMP were 
not recorded on either side. In her sister only oVEMP 
on the left side was registered with a prolonged latency 
of N1 and P1 peaks (data not shown). The results are 
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Fig. 1 Brain and spine MRI in the proband. The left column shows sagittal T2 weighted images of the head and cervical spine (a proband, b control) 
with the measurements of spinal cord thickness at different levels. The middle column shows cross-section of the spinal cord (c proband, d control). 
The right column shows transverse heavy T2 weighted images of sub-millimeter slice thickness displaying the cochlear nerve, pointed with a red 
arrow (e proband, f control)
Table 2 Volumes of cerebrum, cerebellum and the respective gray and white matters in the proband and her sister
n.a. no data available
a Control groups from two different studies: first values [21], second values [22]
b Control group from [23]; underlined are statistically significant differences from both control groups
Brain part Proband (cm3) Control groups (cm3)a Proband’s sister (cm3) Control 
groupb (cm3) 
Cerebrum volume 1030 1181.3 ± 83.1 1187.1 1172 ± 108.1 
1148.5 ± 77.2
Cerebrum gray matter volume 571 672.3 ± 33.3 674.2 579 ± 50.6 
663.2 ± 51
Cerebrum white matter volume 406 384.6 ± 40.5 464.2 435 ± 50.6 
425.3 ± 30
Cerebellum volume 131.1 153.8 ± 10.8 145.2 142 ± 17.5 
134.7 ± 6.8
Cerebellar gray matter volume 98.4 128.1 ± 9.2 111.9 n.a.
112.3 ± 5.9
Cerebellar white matter volume 32.7 26 ± 2.2 33.7 n.a.
22.4 ± 2
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suggestive of a neuropathy of both the superior and the 
inferior vestibular nerves in addition to the involvement 
of the auditory branch of the vestibulocochlear nerve.
Identification of compound heterozygous TWNK mutation
DNA sample of the proband was analyzed by whole 
exome sequencing. After exclusion of variants found 
with a prevalence of 1% or more in the databases of the 
Exome Aggregation Consortium (ExAC, http://exac.
broadinstitute.org/), 1000 Genomes Project (http://
www.1000genomes.org) and the NHLBI GO Exome 
Sequencing Project (ESP, http://evs.gs.washington.edu/
EVS/; all accessed 05/2016) and in a set of 816 exomes 
of Polish patients (ZGM, R. Płoski, unpublished results) 
Fig. 2 Pure tone audiometry (a) and ABRs (b) of the proband. a “O” and “X” symbols denote air conduction thresholds in the right and left ear, 
respectively and “Δ” denotes masked air conduction at high frequencies in the right ear; “[” or “]” denote masked bone conduction. b Shown are ABR 
recordings after click stimulus at an acoustic level of 90 dB normal hearing level (nHL) and presentation rate of 11/s
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in the first line we searched for variants reported in the 
Human Gene Mutation Database (www.hgmd.cf.ac.uk/
ac/index.php) and variants predicted to be pathogenic 
by bioinformatic tools. We found a rare TWNK het-
erozygous missense variant NM_021830.4:c.1196A>G 
(rs863223921), causing the missense change 
NP_068602.2:p.Asn399Ser (Fig. 3a, b) that has been iden-
tified for the first time in 2016 in a Norwegian female 
with PRLTS [10] (Table 3). The variant is predicted to be 
damaging by PolyPhen-2 (score 0.993), SIFT (score 0.02) 
and MutationTaster2 (score 0.998). 
The second TWNK variant was a very rare hete-
rozygous missense change NM_021830.4:c.1802G>A 
(rs141315771), causing the amino acid substitution 
NP_068602.2:p.Arg601Gln (Fig. 3a, b). The p.Arg601Gln 
variant was reported only in the ExAC and ESP data-
bases (accessed 07/2016) with an allele frequency of 
3.29e−5 (4/121412 alleles) and 1.54e-4 (2/13006 alleles), 
respectively but heretofore it has not been identified in 
a homozygous state or associated with any disease. The 
G>A transition is predicted to be damaging by Poly-
Phen-2 (score 0.895), SIFT (score 0.02) and Mutation-
Taster2 (score 0.997).
Presence of the two heterozygous TWNK mutations 
was confirmed in the proband’s sister. The mother was 
a carrier of the p.Asn399Ser mutation, showing that the 
two TWNK mutations are biallelic and the patients are 
compound heterozygous for the mutations (Fig.  3a, b). 
DNA sample from the deceased father was not available 
for the study.
Modelling of p.Asn399Ser and p.Arg601Gln functional 
roles
Multiple sequence alignment demonstrated that 
Asn399 and Arg601 are conserved amino acid resi-
dues among vertebrates (Fig. 4a). In the crystal struc-
ture of the bacteriophage T7 gp4 protein (human 
Twinkle homolog), Asn289 (human Asn399) forms 
two hydrogen bonds with the backbone of Phe296 
(human Trp392). A similar scenario is observed for 
the human protein. The side chain of Asn399, which 
is located on the short helix, forms two hydrogen 
bonds with the backbone atoms of Trp392. Both 
amino acids are located in a region between the linker 
and helicase domains. The p.Asn399Ser mutation dis-
rupts these interactions as Ser399 is located too far 
away to form hydrogen bonds with the main chain of 
Trp392 (Fig. 4b, c). As a result, the entire region may 
adopt a different conformation than in the wild type 
protein. This may impair the correct orientation of 
the linker region and hinder the hexamer/heptamer 
formation [19].
In the T7 gp4 protein the adenine ring of the ATP 
analog is stacked between Arg504 (human Asp591) and 
Tyr535 (human Phe621) [48]. Val514 (human Arg601) 
is positioned next to the adenine ring and placed on 
the same plane. In the human Twinkle protein the key 
Arg504 is replaced by an aspartic acid, which is unable 
to stabilize the adenine ring. Simultaneously, an argi-
nine (Arg601) is introduced at the position occupied by 
a short-chained amino acid (Val514) in the T7 phage. 
According to our 3D model, human Arg601 could adopt a 
conformation, which allows the formation of a hydrogen 
bond with the ATP N7 atom. This conformation can be 
stabilized by hydrogen bond interactions with Asp591. In 
contrast to the T7 phage Arg504, human Arg601 seems 
not to form a cation-π interaction with the adenine ring. 
However, we cannot exclude the possibility that the loop, 
on which both Arg601 and Asp591 are located, assumes a 
different conformation than in our model. This may allow 
Arg601 to adopt a conformation where the adenine ring 
is stabilized via stacking rather than hydrogen bonding. 
The interaction between ATP and Phe621 remains unaf-
fected. Substitution of Arg601 to Gln most likely weakens 
the binding of ATP as Gln is unable to form a hydrogen 
bond with the adenine N7 atom (Fig. 4d, e).
Discussion
Herein, we report the identification of a distinctive 
phenotype of PRLTS5 (OMIM #616138), in which the 
progressive neurologic features, dominating in the phe-
notype, preceded the diagnosis of SNHL and ovarian 
dysfunction. Comprehensive analysis of the patients’ 
phenotype and family history enabled us to establish 
a clinical suspicion of PRLTS. After applying WES the 
underlying cause of the disorder has been explained by 
the detection of compound heterozygous mutations 
in the TWNK. It is the most recently discovered gene 
involved in the pathogenesis of PRLTS that heretofore 
has been reported only in four PRLTS families worldwide.
Pathogenic role of heterozygous TWNK mutations 
have been first discovered in families with autosomal 
dominant progressive external ophthalmoplegia (PEOA3; 
OMIM #609286) [18]. Recessive TWNK mutations are 
causative for mitochondrial DNA depletion syndrome 
7 (MTDPS7; OMIM #271245) also known as infan-
tile-onset spinocerebellar ataxia (IOSCA) [49, 50] and 
were recently identified in patients with PRLTS5 [6, 10] 
(Table 3). There is a substantial phenotypic overlap across 
the conditions resulting from TWNK mutations, particu-
larly in regard to the neurological features. Hearing loss, 
ataxia, myopathy, neuropathy and ophthalmoplegia have 
been reported in patients with each of these diseases. In 
our patients the diagnosis of PEOA3 could be excluded 
based on the presence of ovarian dysgenesis that has not 
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Fig. 3 Identification of TWNK mutations in the analyzed families. a Pedigree of the investigated family. The proband is marked with an arrow. Black 
symbols indicate individuals affected with PRLTS5 and open symbols indicate unaffected individuals; diagonal line denotes the deceased father. 
The TWNK genotypes identified in the family members are reported at the cDNA and protein levels according to the HGVS-nomenclature (http://
varnomen.hgvs.org/; accessed 07/2016). b WES in the proband revealed an A>G transition (upper left panel) and G>A transition (lower left panel), cor-
responding to p.Asn399Ser (AAT>AGT) and p.Arg601Gln (CGG>CAG), respectively, in the TWNK gene. Direct Sanger sequencing of TWNK confirmed 
the presence of the two mutations (right panel). For each mutation sequencing of the forward (top) and the reverse (bottom) strand is shown
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been described in patients with PEOA3, an earlier age of 
disease onset (1–2 vs. 2–8 decade of life) and the identifi-
cation of two TWNK mutations that were not pathogenic 
in the patients’ parents (heterozygous carriers). In con-
trast, MTDPS7 begins very early in life, in children below 
2  years of age; the course of the disease is severe and 
includes optic atrophy, intellectual disability and hepatic 
involvement that were not observed in our patients.
All mutations found in TWNK are missense changes 
and their location does not explain different clinical 
manifestations. It has been hypothesized that even slight 
disturbances to the Twinkle protein, as a consequence 
of TWNK mutation, may affect its enzymatic activity, 
DNA binding ability, interaction with subunits or stabil-
ity and result in a less-effective enzyme [51, 52]. Differ-
ent bioinformatics tools predicted a deleterious effect of 
p.Asn399Ser and p.Arg601Gln on the protein function. 
In the applied 3D model we showed that p.Asn399Ser 
may affect the oligomeric Twinkle structure, crucial for 
the enzyme’s ability to unwind the DNA. A consequence 
of p.Arg601Gln appears to be impaired binding and 
hydrolysis of ATP, which is of paramount importance for 
enzyme functioning.
No formal criteria have been elaborated to facilitate 
accurate recognition of PRLTS. In the first line, karyo-
type analysis should be performed to exclude Turner 
syndrome or other abnormalities of the X chromosome 
as approximately half of females with Turner syndrome 
(gonadal dysgenesis) suffer from hearing loss [53]. Next, 
other causes of sensorineural hearing loss (SNHL) and 
ovarian dysfunction should be considered. Both condi-
tions are genetically heterogeneous and testing of causa-
tive mutations in known genes is appropriate. In patients 
with neurologic involvement, the phenotype of PRLTS 
may overlap clinically with a mild form of peroxisomal 
d-bifunctional protein deficiency (DBP type IV; OMIM 
#261515). Presence of ovarian dysgenesis is considered 
the major clinical feature differentiating PRLTS from 
DBP type IV [9]. A comprehensive analysis of WES data 
provided us with a wealth of information on the genetic 
constitution of the proband. Except for two TWNK 
mutations no other mutation has been identified, which 
alone or in combination with other pathogenic variants 
could account for the clinical features observed in the 
proband. After identifying both TWNK mutations in the 
proband’s sister and confirming their biallelic status we 
could unequivocally establish the molecular genetic basis 
of the disease in the studied family. Our results provide 
further evidence that mutations in TWNK cause PRLTS5 
[6, 10].
Neurological features in PRLTS have been observed 
in patients with mutations either in HSD17B4, CLPP 
or TWNK genes, i.e. in three out of five known PRLTS 
genes [5, 6, 9–12, 16, 17]. However, involvement of the 
nervous system seems to be a constant finding only 
in patients with TWNK mutations. In contrast to our 
patients in other individuals with PRLTS5 the neurologi-
cal problems became noticeable later in life after hearing 
loss and ovarian dysfunction have been diagnosed [6, 10, 
13]. The proband had a subtle atrophy of the cerebellum, 
a feature previously described in PRLTS patients [9, 10]. 
Significantly distorted proportion between the cerebel-
lum white and grey matters represents a novel finding 
in PRLTS patients, which was independently confirmed 
using two different control groups. Atrophy of cervical 
medulla, present in both of our patients, was a feature 
of another PRLTS5 patient, who also shared the TWNK 
p.Asn399Ser mutation [10].
Audiological examination and neuroimaging stud-
ies revealed that hearing loss in PRLTS5 patients has a 
complex background. Analysis of the hearing threshold 
together with OAE (absent at higher frequencies) pointed 
Table 3 Comparison of demographic and molecular findings in PRLTS patients with TWNK mutation
N no, Y yes, n.a. no data available
Family # and 
origin












N Two sisters rs672601361 c.1321T>G p.Trp441Gly 46,XX [6]
rs369588002 c.1519G>A p.Val507Ile
3. Norwegian N One female rs770917763 c.968G>A p.Arg323Gln 46,XX [10]
rs863223921 c.1196A>G p.Asn399Ser
4. Moroccan Y Two sisters and 
brother
rs764669712 c.793C>T p.Arg265Cys n.a. [13]
rs764669712 c.793C>T p.Arg265Cys
5. Polish N Two sisters rs863223921 c.1196A>G p.Asn399Ser 46,XX Present study
rs141315771 c.1802G>A p.Arg601Gln
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Fig. 4 Multiple protein sequence alignment and 3D structure of the human Twinkle protein in regions encompassing p.Asn399Ser and 
p.Arg601Gln mutations. a Multiple protein sequence alignment of selected sequences. Two regions of the twinkle protein are shown: (i) the region 
joining the linker and the helicase domains (Region I) and (ii) the region involved in stabilizing the adenine ring of ATP (Regions II and III). The num-
bers above the alignment correspond to the amino acid position in the human protein sequence. (b–c) Two interacting monomers of the Twinkle 
protein are colored white and blue. Changes in the conformation of a region next to the linker domain in p.Asn399Ser mutant (b) and in wild type 
(c) proteins are shown. (d–e) Changes in hydrogen bonds network resulting in weakened ATP binding in the p.Arg601Gln mutant (d) as compared 
to wild type (e) protein are depicted
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to impairment of the cochlear function. While lack of 
stapedius reflexes and ABRs, together with normal tym-
panometry and the presence of OAE, were classical fea-
tures of auditory neuropathy. Absent ABRs suggested 
that the defect localizes to the synapse between the hair 
cells and the auditory nerve. As imaging studies revealed 
partial atrophy of the vestibulocochlear nerve, their ves-
tibular and cochlear components and the patients mani-
fested peripheral neuropathy, we assume that the disease 
process affects the vestibulocochlear nerve fibers, particu-
larly their distal parts. It should be also taken into account 
that absent ABRs may represent a progressed state of 
the disease, which has begun in the proximal part of the 
vestibulocochlear nerve as it is observed in other heredi-
tary neurological diseases affecting mitochondrial func-
tion such as Friedreich’s ataxia or Charcot–Marie–Tooth 
(excluded in the proband based on genetic tests) [54, 55].
Partial atrophy of the vestibular nerves was less marked 
than the atrophy of the cochlear nerve and functionally 
sufficient to provide normal results of the vestibulo-ocu-
lar reflex in caloric tests and to some extend of the rota-
tional testing. However, the number of vestibular nerve 
fibers discharging synchronously appears insufficient to 
obtain normal results of VEMP responses. It should be 
also considered that abnormal or absent VEMPs could be 
a consequence of the neuropathological process affect-
ing the medial vestibulospinal tract (VEMP descending 
pathway) as diminished cervical enlargement was found 
in both patients. Asymptomatic vestibular disorders are 
commonly observed in patients with auditory neuropa-
thy accompanied by peripheral neuropathy [56].
Conclusions
Our study presents a detailed and systematic assess-
ment of the auditory and nervous systems in patients 
with PRLTS5, which sheds new insight on the pheno-
type and disease process of the mitochondrial disorder. 
We show for the first time in PRLTS patients (1) a com-
plex mechanism of hearing impairment, comprising 
of cochlear dysfunction and dyssynchronous auditory 
nerve function, (2) partial atrophy of the vestibuloc-
ochlear nerves and their auditory and vestibular parts 
and (3) aberrant proportion of the cerebellum white 
and grey matters. Genetic workup provided further evi-
dence on the causative role of TWNK mutations. From 
the seven known TWNK mutations underlying PRLTS5 
one has recurred in our patients and its detection in 
the second individual with PRLTS5 confirms the patho-
genic potential of the variant. The second TWNK muta-
tion has not been reported in the context of any disease 
and its identification represents a novel genetic associa-
tion with PRLTS5.
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